Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, ...

Tonix Pharma Q4 earnings: revenue up 109% on early Tonmya launch, but losses persist. Click here to read my most recent analysis of TNXP stock.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Tonix Pharma (TNXP – Research Re ...

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.

CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization. ・Investors are also watching TNX ...

TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

The U.S. stocks ended mostly higher on Monday, with tech stocks leading the gains, as investors await the Federal Reserve's policy meeting that concludes on Wednesday. Wednesday marked the first time ...

About Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that a poster on Tonmya(TM) (cyclobenzaprine HCl sublingual ...

We've identified the following companies as similar to Tonix Pharmaceuticals Holding Corp because they operate in a related industry or sector. We also considered size, growth, and various financial ...

BERKELEY HEIGHTS, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) received approval to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, ...